Voriconazole

Drugs of the Future

Volumn 21, Issue 3, 1996, Pages 266-271

  Fromtling, Robert A ^a   Castaner J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CRYPTOCOCCUS; DOG; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME INHIBITION; EYE TOXICITY; GUINEA PIG; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; SHORT SURVEY; YEAST;

EID: 0029942358     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.03.343618     Document Type: Short Survey

References (37)

1. Ray, S.J., Richardson, K. (Pfizer, Inc.). Triazole antifungal agents. EP 440372, JP 92211078, US 5278175.
2. Rex, J.H., Rinaldi, M.G., Pfaller, M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39: 1-8.
3. Fan-Havard, P., Capana, D., Smith, S.M., Mangia, A., Eng, R.H.K Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1991, 35: 2302-5.
4. Wingard, J.R., Merz, W.G., Rinaldi, M.G , Johnson, T.R., Karp, J.E., Saral, R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991, 325: 1274-7.
5. Heinic, G.S., Stevens, D.A., Greenspan, D., MacPhail, L.A , Dodd, C.L., Stringari, S., Strull, W.M., Hollander, H. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Med Oral Pathol 1993, 76: 711-5
6. Odds, F.C. Resistance of yeasts to azole-derivative antifungals J Antimicrob Chemother 1993, 31: 463-71.
7. Baily, G.G., Perry, F M., Dennig, D.W., Mandal, B.K. Fluconazole resistant candidosis in an HIV cohort. AIDS 1993. 8: 787-92
8. Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., Trautmann, M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994, 32: 2092-8.
9. Dupont, B., Denning, D.W., Marriott, D., Sugar, A., Viviani, M.A., Sirisanthana, T. Mycoses in AIDS patients. J Med Veterinary Mycol 1994, 32(Suppl. 1): 65-77.
10. Viviani, M A. Opportunistic fungal infections in patients with acquired immune deficiency syndrome. Chemotherapy 1992, 38(Suppl. 1): 35-42.
11. Denning, D.W., Follansbee, S.E., Scolaro, M., Norris, S., Edelstein, H., Stevens, D.A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. New Engl J Med 1991. 324: 654-62.
12. Dupont, B., Graybill, J.R., Armstrong, D., Larouche, R., Tuoze, J.E., Wheat, L.J. Fungal infections in AIDS patients. J Med Veterinary Mycol 1992, 30(Suppl. 1): 19-28.
13. Armstrong, D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993, 16: 1-9.
14. De Repentigny, L., Reiss, E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 1984, 6. 301-12.
15. Kurup, V.P., Kumar, A. Immunodiagnosis of aspergillosis. Clin Microbiol Rev 1991, 4: 439-56.
16. Rinaldi, M.G. Invasive aspergillosis. Rev Infect Dis 1983, 5: 1061-77.
17. Richardson, K., Bell, A.S., Dickinson, R.P., Naryanaswami, S., Ray, S.J. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Synthesis and SAR. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F69.
18. Troke, P.F., Bell, A.S., Dickinson, R.P., Hitchcock, C.A., Jezequel, S., Narayanaswami, S., Ray, S.J., Richardson, K. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of systemic fungal infections: Discovery and antifungal properties. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F70.
19. Fromtling, R.A. Fluconazole (UK-49,858). Drugs Fut 1985,10: 983-4.
20. Fromtling, R A. Fluconazole (Diflucan®): A new antifungal triazole. Med Actual/Drugs Today 1990, 26: 547-56.
21. Goa, K.L., Barradell, L.B. Fluconazole: An update. Drugs 1995, 50: 658-90.
22. Barchiesi, F., Restrepo, M., McGough, D.A., Rinaldi, M.G. In vitro activity of a new antifungal triazole: UK-109,496. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F71.
23. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. NCCLS, Villanova, PA 1995.
24. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-P. NCCLS, Villanova, PA 1992.
25. Pye, G.W., Oliver, G.P., Troke, P.F. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections. Antifungal activity and selectivity in vitro. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F72
26. Odds, F.C., Abbott, A.B., Pye, G., Troke, P.F. Improved method for estimation of azote antifungal inhibitory concentration against Candida species, based on azole/antibiotic interactions J Med Veterinary Mycol 1986, 24: 305-11.
27. Troke, P. F. In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses. In: Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development, J.W. Rippon and R.A. Fromtling (Eds.), Marcel Dekker, New York, 1993, 199-214.
28. McGinnis, M.R., Pasarell, L., Cooper, C.R. Jr. In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst E76.
29. Troke, P.F., Brammer, K.W., Hitchcock, C.A., Yonren, S., Sarantis, N. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F73.
30. Hitchcock, C.A., Andrews, R.J., Lewis, B.G.H., Troke, P.F. UK-109,946, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Cryptococcus. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F75.
31. Hitchcock, C.A., Andrews, R.J., Lewis, B.G.H., Troke, P.F. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Aspergillus. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F74.
32. Jezequel, S.G., Clark, M , Cole, S., Evans, K.E., Wastall, P. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pre-clinical pharmacokinetics. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F76.
33. Jezequel, S.G., Clark, M., Evans, K.E , Roffey, S., Wastall, P., Webster, R. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in animals. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F77.
34. Patterson, B.E., Coates, P.E. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F78.
35. Patterson, B.E., Roffey, S., Jezequel, S.G., Jones, B. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in man. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F79.
36. Denning, D., Del Favero, A., Gluckman, E., Norfolk, D., Ruhnke, M., Yonren, S., Troke, P , Sarantis, N. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis. 35th lntersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F80.
37. Dupont, B., Denning, D., Lode, H., Yonren, S., Troke, P., Sarantis, N. UK-109.496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst F81.